Stephen K. Burley
Corporate Officer/Principal at The Rockefeller University
Profile
Stephen K.
Burley is the founder of Prospect Genomics, Inc. He is currently an Adjunct Professor at The Rockefeller University.
Previously, he was the Director at Cascadian Therapeutics LLC in 2008 and the Chief Scientific Officer & SVP-Research at SGX Pharmaceuticals, Inc. from 2002 to 2011.
Burley received his doctorate degrees from Harvard University and the University of Oxford, and his undergraduate degree from the University of Western Ontario.
Stephen K. Burley active positions
| Companies | Position | Start |
|---|---|---|
| The Rockefeller University | Corporate Officer/Principal | 1997-05-31 |
Former positions of Stephen K. Burley
| Companies | Position | End |
|---|---|---|
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2011-04-17 |
| CASCADIAN THERAPEUTICS INC (USA) | Director/Board Member | 2008-09-03 |
Prospect Genomics, Inc.
 Prospect Genomics, Inc. Packaged SoftwareTechnology Services Prospect Genomics, Inc. developed computational technology solutions for the pharmaceutical field. The company was headquartered in San Diego, CA. | Founder | - |
Training of Stephen K. Burley
| Harvard University | Doctorate Degree |
| University of Oxford | Doctorate Degree |
| University of Western Ontario | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Health Technology |
Prospect Genomics, Inc.
Prospect Genomics, Inc. Packaged SoftwareTechnology Services Prospect Genomics, Inc. developed computational technology solutions for the pharmaceutical field. The company was headquartered in San Diego, CA. | Technology Services |
- Stock Market
- Insiders
- Stephen K. Burley